KR20200012972A - 세포 배양 방법 - Google Patents

세포 배양 방법 Download PDF

Info

Publication number
KR20200012972A
KR20200012972A KR1020197038895A KR20197038895A KR20200012972A KR 20200012972 A KR20200012972 A KR 20200012972A KR 1020197038895 A KR1020197038895 A KR 1020197038895A KR 20197038895 A KR20197038895 A KR 20197038895A KR 20200012972 A KR20200012972 A KR 20200012972A
Authority
KR
South Korea
Prior art keywords
cysteine
cystine
recombinant protein
tryptophan
total amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197038895A
Other languages
English (en)
Korean (ko)
Inventor
야히아 바셈 벤
레티샤 말페테스
나딘 코하노프스키
길 레너
산드린 두란
앤드루 제프리 예이츠
Original Assignee
유씨비 바이오파마 에스알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59270991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20200012972(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유씨비 바이오파마 에스알엘 filed Critical 유씨비 바이오파마 에스알엘
Priority to KR1020247019609A priority Critical patent/KR20240096888A/ko
Priority to KR1020257034169A priority patent/KR20250156183A/ko
Publication of KR20200012972A publication Critical patent/KR20200012972A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020197038895A 2017-05-31 2018-05-29 세포 배양 방법 Ceased KR20200012972A (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020247019609A KR20240096888A (ko) 2017-05-31 2018-05-29 세포 배양 방법
KR1020257034169A KR20250156183A (ko) 2017-05-31 2018-05-29 세포 배양 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1708655.4A GB201708655D0 (en) 2017-05-31 2017-05-31 Cell culture methods
GB1708655.4 2017-05-31
PCT/EP2018/064102 WO2018219968A1 (en) 2017-05-31 2018-05-29 Cell culture methods

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020247019609A Division KR20240096888A (ko) 2017-05-31 2018-05-29 세포 배양 방법
KR1020257034169A Division KR20250156183A (ko) 2017-05-31 2018-05-29 세포 배양 방법

Publications (1)

Publication Number Publication Date
KR20200012972A true KR20200012972A (ko) 2020-02-05

Family

ID=59270991

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197038895A Ceased KR20200012972A (ko) 2017-05-31 2018-05-29 세포 배양 방법
KR1020247019609A Pending KR20240096888A (ko) 2017-05-31 2018-05-29 세포 배양 방법
KR1020257034169A Pending KR20250156183A (ko) 2017-05-31 2018-05-29 세포 배양 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247019609A Pending KR20240096888A (ko) 2017-05-31 2018-05-29 세포 배양 방법
KR1020257034169A Pending KR20250156183A (ko) 2017-05-31 2018-05-29 세포 배양 방법

Country Status (21)

Country Link
US (3) US12077796B2 (https=)
EP (2) EP3630946B1 (https=)
JP (3) JP7460370B2 (https=)
KR (3) KR20200012972A (https=)
CN (2) CN119326882A (https=)
AU (2) AU2018276376C1 (https=)
BR (1) BR112019024390A2 (https=)
CA (1) CA3065661A1 (https=)
CL (1) CL2019003459A1 (https=)
CO (1) CO2019012871A2 (https=)
EA (1) EA201992828A1 (https=)
ES (1) ES2978394T3 (https=)
GB (1) GB201708655D0 (https=)
HR (1) HRP20240585T1 (https=)
HU (1) HUE066922T2 (https=)
IL (2) IL270880B2 (https=)
MX (1) MX2019014140A (https=)
MY (1) MY193535A (https=)
PL (1) PL3630946T3 (https=)
RU (2) RU2021128024A (https=)
WO (1) WO2018219968A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
JP2023554489A (ja) * 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
GB202105424D0 (en) * 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes
WO2025262319A1 (en) 2024-06-21 2025-12-26 Boehringer Ingelheim International Gmbh Modifying blue color formation in bioprocesses

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
EP1623019B2 (en) 2003-05-15 2017-01-25 Wyeth LLC Restricted glucose feed for animal cell culture
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
SI2078071T1 (sl) * 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
US8030027B2 (en) * 2008-04-29 2011-10-04 St. Jude Children's Research Hospital Method for enhancing recombinant antibody production
US8252557B2 (en) 2008-10-28 2012-08-28 Chugai Seiyaku Kabushiki Kaisha Peptide-containing culture medium for culturing animal cell
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
RU2563353C2 (ru) 2010-04-26 2015-09-20 Новартис Аг Улучшенная среда для культивирования клеток
PL2563906T3 (pl) 2010-04-26 2018-04-30 Novartis Ag Sposób hodowli komórek cho
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
WO2012145682A1 (en) * 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP4527855A3 (en) * 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
JP2016513478A (ja) * 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法
CN106715707A (zh) 2014-06-18 2017-05-24 免疫医疗公司 包含n‑乙酰半胱氨酸的细胞培养方法和培养基
WO2016108765A1 (en) 2014-12-29 2016-07-07 Wirojpaisi Wanlop Engine combustion system oxygen efficiency enhancing device with raised electrical voltage and improved installation method
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
KR102425040B1 (ko) 2016-04-28 2022-07-25 메르크 파텐트 게엠베하 단백질 내 트리술파이드 수준을 감소시키기 위한 방법
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
WO2018018613A1 (zh) * 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN106222129A (zh) 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods

Also Published As

Publication number Publication date
IL270880A (en) 2020-01-30
CN110741077B (zh) 2024-10-11
MY193535A (en) 2022-10-18
JP2022153421A (ja) 2022-10-12
RU2758674C2 (ru) 2021-11-01
JP7460370B2 (ja) 2024-04-02
EP3630946B1 (en) 2024-03-27
WO2018219968A1 (en) 2018-12-06
IL317828A (en) 2025-02-01
IL270880B2 (en) 2025-05-01
EP4397682A3 (en) 2024-08-21
AU2018276376C1 (en) 2025-01-30
HRP20240585T1 (hr) 2024-07-19
RU2021128024A (ru) 2021-12-08
EA201992828A1 (ru) 2020-04-21
RU2019143742A (ru) 2021-06-30
HUE066922T2 (hu) 2024-09-28
AU2024259881A1 (en) 2024-11-28
BR112019024390A2 (pt) 2020-07-14
CN110741077A (zh) 2020-01-31
JP7406593B2 (ja) 2023-12-27
EP4397682A2 (en) 2024-07-10
CO2019012871A2 (es) 2020-01-17
PL3630946T3 (pl) 2024-07-01
JP2020521490A (ja) 2020-07-27
GB201708655D0 (en) 2017-07-12
AU2018276376A1 (en) 2019-12-12
JP7560420B2 (ja) 2024-10-02
AU2018276376B2 (en) 2024-08-15
JP2021185185A (ja) 2021-12-09
IL270880B1 (en) 2025-01-01
AU2024259881B2 (en) 2025-02-13
MX2019014140A (es) 2020-02-07
ES2978394T3 (es) 2024-09-11
KR20250156183A (ko) 2025-10-31
US20250051824A1 (en) 2025-02-13
CN119326882A (zh) 2025-01-21
EP3630946C0 (en) 2024-03-27
CL2019003459A1 (es) 2020-04-24
EP3630946A1 (en) 2020-04-08
US12077796B2 (en) 2024-09-03
RU2019143742A3 (https=) 2021-06-30
CA3065661A1 (en) 2018-12-06
US20250066832A1 (en) 2025-02-27
US20200239923A1 (en) 2020-07-30
KR20240096888A (ko) 2024-06-26

Similar Documents

Publication Publication Date Title
US20250066832A1 (en) Cell culture methods
EP3717631B1 (en) Cell culture methods
CN110272492A (zh) 抗αβTCR抗体
EA044551B1 (ru) Способы культивирования клеток
HK40114294A (zh) 细胞培养方法
US20240425894A1 (en) Cell culture processes
BR122024024868A2 (pt) Métodos de cultura celular
KR20250022781A (ko) 세포 배양 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20250731

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2019 7038895

Appeal request date: 20240612

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024101001355

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2024101001355; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : APPEAL AGAINST DECISION TO DECLINE REFUSAL

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104